TX-OURO
Ouro, a global financial services and technology innovator, and the Real Madrid Football Club today announced a strategic partnership agreement to develop and deliver co-branded financial solutions to fans in key markets globally, including the United States, Mexico, Brazil, Portugal, France and the United Arab Emirates. The alliance makes Ouro the exclusive partner of the men's and women's football teams for the prepaid, debit and credit card product categories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240424106690/en/
The signing event held April 15 in Madrid with Ouro founders Bertrand Sosa and Roy Sosa and Emilio Butragueño, Real Madrid’s Director of Institutional Relations. (Photo: Business Wire)
From the April 15 signing event in Madrid, Emilio Butragueño, Real Madrid’s Director of Institutional Relations, commented, “It’s hugely gratifying. They are leaders in financial services who will partner with us in countries around the world. We share a commitment to values like constant reinvention and trying to get better everyday that are as fundamental to our organizations as integrity. We look forward to an enduring and rewarding partnership.”
As an official partner to Real Madrid in these countries, Ouro will unite the Real Madrid brand and Madridista loyalty program benefits with Ouro branded products and their unique functionalities – this includes Ouro’s flagship Netspend brand which pioneered prepaid debit for underserved consumers across the U.S., and its more recently developed X World Wallet that offers a multi-currency wallet and payments app for mobile, multicultural consumers.
“We are honored to join forces with such a storied and beloved global brand to make financial empowerment products more accessible to more people,” said Bertrand Sosa, president and chief brand officer, Ouro. “This unique opportunity to help people take their money further so they can experience more of what they love is the motivation behind our work, and to have Real Madrid collaborate with us to deliver even more value to such a passionate fan base is very special.”
By joining sports loyalty with financial solutions, Ouro and Real Madrid aim to deepen the Madridistas’ connection with their club, maximize the value of their money and promote financial responsibility and accessibility. The partnership also supports Ouro’s strategic focus on innovation, growth, and expansion to global markets.
“We are proud to announce our partnership with Real Madrid, a global icon that shares our values of excellence, winning spirit, solidarity, and humility,” added Roy Sosa, Ouro CEO and Co-founder. “Today we start a movement that transcends sports. Together, we will empower millions of fans and customers to achieve their financial goals and turn their dreams into reality.”
The partnership will soon launch a co-branded Netspend card featuring the Real Madrid brand in the U.S. in anticipation of the team’s upcoming U.S. Summer Tour.
The partners have also started joint development of a co-branded financial product combining the loyalty benefits of the Madridista Club membership with a digital multi-currency wallet they will begin rolling out to fans around the world later this year. Loyal Real Madrid fans can expect these payment products to bring them even closer to the action, with special access to discounts and experiences at the point of sale and beyond.
Fans who want to be among the first to know about availability where they live can now join the waitlist at ouro.com/realmadrid.
About Ouro
Ouro is a global, vertically-integrated financial services and technology company dedicated to the delivery of innovative financial empowerment solutions to consumers worldwide. Ouro's financial products and services span prepaid, debit, cross-border payments, and loyalty solutions for consumers and enterprise partners. Since its founding in 1999 by industry pioneers Roy and Bertrand Sosa, Ouro products have processed almost a trillion dollars in transaction volume and served millions of customers worldwide. The company is headquartered in Austin, Texas with regional offices across the world. For more information, visit ouro.com.
About Real Madrid
Real Madrid C.F. is a sport entity with 122 years of history. It is the club with the most European Cups of both football (14) and basketball (11) and was awarded by FIFA as the Best Club of the twentieth century. Real Madrid has millions of fans in all corners of the world, with more than 534 million followers on social media, being the strongest football brand in the world according to Brand Finance for the second year in a row and also the highest earning football club in the world in the 22-23 season (Football Money League by Deloitte). More information about Real Madrid C.F. is available at www.realmadrid.com, the most visited football club website for the seventh consecutive year.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424106690/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom